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Abstract
We have previously developed mouse models of HER-2-positive cervical cancer. Tumors
in nude mice had histological structures similar to the original tumor and were stained by
anti-HER-2 antibody in the same pattern as the patient’s cancer. We have also previously
developed tumor-targeting Salmonella typhimurium A1-R and have demonstrated its effica-
cy against patient-derived tumor mouse models, both alone and in combination. In the cur-
rent study, we determined the efficacy of S. typhimurium A1-R in combination with
trastuzumab on a patient-cancer nude-mouse model of HER-2 positive cervical cancer.
Mice were randomized to 5 groups and treated as follows: (1) no treatment; (2) carboplati-
num (30 mg/kg, ip, weekly, 5 weeks); (3) trastuzumab (20 mg/kg, ip, weekly, 5 weeks); (4)
S. typhimurium A1-R (5 × 107 CFU/body, ip, weekly, 5 weeks); (5) S. typhimurium A1-R (5
× 107 CFU/body, ip, weekly, 5 weeks) + trastuzumab (20 mg/kg, ip, weekly, 5 weeks). All
regimens had significant efficacy compared to the untreated mice. The relative tumor vol-
ume of S. typhimurium A1-R + trastuzumab-treated mice was smaller compared to trastuzu-
mab alone (p = 0.007) and S. typhimurium A1-R alone (p = 0.039). No significant body
weight loss was found compared to the no treatment group except for carboplatinum-treated
mice (p = 0.021). Upon histological examination, viable tumor cells were not detected, and
replaced by stromal cells in the tumors treated with S. typhimurium A1-R + trastuzumab.
The results of the present study suggest that S. typhimurium A1-R and trastuzumab in com-
bination are highly effective against HER-2-expressing cervical cancer.
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Introduction
Cervical cancer is the second most common cancer in women [1]. There were 454,000 cases
and 200,000 deaths in 2010 worldwide and 11,000 new cases and 3,870 deaths from cervical
carcinoma in the U.S. [2, 3]. Paclitaxel, carboplatin, cisplatinum, bleomycin, mitomycin-C, vin-
cristine and irinotecan are used for cervical cancer [4]. However, there is no standard treatment
for cervical cancer.
The incidence of HER-2 positivity in cervical cancer was reported from 1% to 21% [5], and
overexpression of HER-2 has been associated with more advanced stages and a worse progno-
sis [6, 7].
We previously developed mouse models of HER-2-positive patient cervical cancer [8]. Our
laboratory has also previously developed a genetically-modified bacteria strain, Salmonella
typhimurium A1-R, selected for tumor-targeting in vivo. S. typhimurium A1-R is auxotrophic
for leu and arg [9]. The strain targets and grows in tumors. In contrast, normal tissue is cleared
of these bacteria even in immunodeficient athymic mice.
S. typhimurium A1-R is effective against prostate cancer [10], breast cancer [11, 12], pancre-
atic cancer [13–16], glioma [17, 18], lung cancer [19], fibrosarcoma [20, 21], osteosarcoma [22]
and ovarian cancer [23].
In the present study, we demonstrate the efficacy of S. typhimurium A1-R in combination
with trastuzumab on mouse models of patient cervical cancer expressing HER-2.
Materials and Methods
Ethics Statement
All animal studies were conducted with an AntiCancer Institutional Animal Care and Use
Committee (IACUC)-protocol specifically approved for this study and in accordance with the
principals and procedures outlined in the National Institute of Health Guide for the Care and
Use of Animals under Assurance Number A3873-1. In order to minimize any suffering of the
animals the use of anesthesia and analgesics were used for all surgical experiments. Animals
were anesthetized by intramuscular injection of a 0.02 ml solution of 20 mg/kg ketamine, 15.2
mg/kg xylazine, and 0.48 mg/kg acepromazine maleate. The response of animals during sur-
gery was monitored to ensure adequate depth of anesthesia. Ibuprofen (7.5 mg/kg orally in
drinking water every 24 hours for 7 days post-surgery) was used in order to provide analgesia
post-operatively in the surgically-treated animals. The animals were observed on a daily basis
and humanely sacrificed by CO2 inhalation when they met the following humane endpoint cri-
teria: prostration, skin lesions, significant body weight loss, difficulty breathing, epistaxis, rota-
tional motion and body temperature drop. The use of animals was necessary to understand the
in vivo efficacy, in particular, anti-metastatic efficacy of the agents tested. Animals were housed
with no more than 5 per cage. Animals were housed in a barrier facility on a high efficiency
particulate air (HEPA)-filtered rack under standard conditions of 12-hour light/dark cycles.
The animals were fed an autoclaved laboratory rodent diet (Supp. Information S1).
Animals
Female athymic (nu/nu) nude mice (AntiCancer, Inc., San Diego, CA), 4–6 weeks old, were
used in this study. Mice were kept in a barrier facility under HEPA filtration. Mice were fed
with autoclaved laboratory rodent diet. All mouse surgical procedures and imaging were per-
formed with the animals anesthetized by intramuscular injection of a 0.02 ml solution of 20
mg/kg ketamine, 15.2 mg/kg xylazine, and 0.48 mg/kg acepromazine maleate. All animal stud-
ies were conducted with an AntiCancer Institutional Animal Care and Use Committee
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(IACUC)-protocol specifically approved for this study and in accordance with the principals
and procedures outlined in the National Institute of Health Guide for the Care and Use of Ani-
mals under Assurance Number A3873-1.
Specimen collection
The patient provided written informed consent and the tumor specimen was procured under
the approval of the Institutional Review Board of the University of California San Diego.
Subcutaneous implantation of patient cervical cancer
Tumor tissues were obtained from the HER-2-positive cervical cancer patient at surgery and
cut into fragments (3-mm3) and transplanted subcutaneously in nude mice [8].
Tissue histology
Tumor tissue was removed along with surrounding normal tissues at the time of resection. The
tissues were fixed in 10% formalin and embedded in paraffin before sectioning and staining.
Tissue sections (3 μm) were deparaffinized in xylene and rehydrated in an ethanol series. He-
matoxylin and eosin (H&E) staining was performed according to standard protocols. For
immunohistochemistry, sections (5 μm) were then treated for 30 min with hydrogen peroxide
(0.3%) to block endogenous peroxidase activity. The sections were subsequently washed with
PBS and unmasked in citrate antigen-unmasking solution (Mitsubishi Kagaku Iatron, Inc.,
Tokyo, Japan) in a water bath for 40 min at 98°C. After incubation with 10% normal goat
serum, the sections were incubated with anti-HER-2/ErbB2 (1:100; Cell Signaling Technology,
Inc., Danvers, MA, USA) at 4°C overnight. The binding of primary antibodies was detected
using anti-rabbit secondary antibodies and an avidin/biotin/horseradish peroxidase complex
(DAKO Cytomation, Kyoto, Japan) for 30 min at room temperature. The labeled antigens were
visualized with the DAB kit (DAKO Cytomation). Finally, the sections were counterstained
with hematoxylin and examined with a BH-2 microscope (Olympus, Tokyo, Japan) equipped
with an INFINITY1 2.0 megapixel CMOS digital camera (Lumenera Corporation, Ottawa,
Canada). All images were acquired using INFINITY ANALYZE software (Lumenera Corpora-
tion) without post-acquisition processing.
Treatment of patient cervical cancer growing in nude mice
Six weeks after implantation, the mice were randomized to 5 groups and treated as follows: (1)
no treatment; (2) carboplatinum (Selleck Chemicals, Houston, TX, USA, 30 mg/kg, ip, weekly,
5 weeks); (3) trastuzumab (Genentech, Inc., South San Francisco, CA, USA, 20 mg/kg, ip,
weekly, 5 weeks); (4) S. typhimurium A1-R (5 × 107 CFU/body, ip, weekly, 5 weeks); and (5) S.
typhimurium A1-R (5 × 107 CFU/body, ip, weekly, 5 weeks) + trastuzumab (20 mg/kg, ip,
weekly, 5 weeks) were co-administered. Each treatment arm comprised 6 tumor-bearing mice.
Tumor size was evaluated every 3 or 4 days by caliper measurements and the approximate vol-
ume of the tumor was calculated using the formula 4/3π (d/2)2 D/2; where d is the minor
tumor axis and D is the major tumor axis. Body weight of the mice was measured on a balance
every 3 or 4 days. Relative tumor volume and body weight were calculated by comparison to
day-1 values. Tumors were imaged with a Canon EOS 60D digital camera with an EF–S18–55
IS lens (Canon, Tokyo, Japan) and harvested for analysis.
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Evaluation of histopathological response
Histopathological response to chemotherapy was defined according to Evans’s grading scheme:
Grade I, little (<10%) or no tumor cell destruction is evident; Grade II a, destruction of 10%-
50% of tumor cells; Grade II b, destruction of 51%-90% of tumor cells; Grade III, few (<10%)
viable-appearing tumor cells are present; Grade IV, no viable tumor cells are present [24, 25].
Statistical analysis
PASW Statistics 18.0 (SPSS, Inc) was used for all statistical analyses. Final tumor volumes (at
day-36) in each treatment group were compared to the untreated control using a 2-tailed Stu-
dent’s t-test. A p-value of 0.05 was considered statistically significant for all comparisons.
Results and Discussion
Histology of the original tumor is preserved in the mouse
Sheet-like growth without gland formation and stromal tissue with fibroblastic proliferation,
which penetrated into nests of cancer cells was observed in the H&E stained sections of the
original tumor (Fig 1A). Oval- to spindle-shaped cancer cells with high nuclear/cytoplasmic
ratio were found in high magnification images (Fig 1B). In the immunostained sections with
anti-HER-2 antibody, the membrane and the cytoplasm of cancer cells were strongly stained,
but no staining was found in the stromal tissue (Fig 1C and 1D). All mouse-grown cervical pa-
tient-derived tumor had histological structures similar to the original tumor and were stained
by anti-human HER-2 antibody (Fig 1E–1H), suggesting that the model recapitulates the bio-
logical behavior of the original tumor [8].
S. typhimurium A1-R + trastuzumab combination is effective against
patient-derived cervical cancer growing in nude mice
The relative tumor volumes at day-36, compared to day-1, of each group were as follows: (1)
no treatment: 10.23 ± 2.91; (2) carboplatinum: 1.02 ± 0.43; (3) trastuzumab: 1.23 ± 0.50; (4) S.
typhimurium A1-R: 0.54 ± 0.40; (5) S. typhimurium A1-R + trastuzumab: 0.08 ± 0.04 (Fig 2A).
All regimens had significant efficacy compared to the untreated mice. The relative tumor
Fig 1. Tumor histology and immunohistochemistry. (A) H & E-stained section of the original patient
tumor. (B) High magnification image of (A). (C) Immunostained section of the original patient tumor using anti-
HER-2 antibody. (D) High magnification image of (C). (E) H & E-stained section of the mouse-grown tumor.
(B) High magnification image of (F). (G) Immunostained section of the mouse-grown tumor using an anti-
HER-2 antibody. (H) High magnification image of (G). Scale bars: 200 μm (A, C, E and G) and 25 μm (B, D, F
and H).
doi:10.1371/journal.pone.0120358.g001
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volume of S. typhimurium A1-R + trastuzumab-treated mice was smaller than with trastuzu-
mab treatment alone (p = 0.007) or S. typhimurium A1-R treatment alone (p = 0.039) (Fig 2A).
The relative body weight at day-36, compared to day-1, of each group was as follows: (1) no
treatment: 1.13 ± 0.14; (2) carboplatinum: 0.93 ± 0.06; (3) trastuzumab: 1.04 ± 0.22; (4) S.
typhimurium A1-R: 1.09 ± 0.06; (5) S. typhimurium A1-R + trastuzumab: 1.00 ± 0.08. No sig-
nificant body weight loss was found compared to the untreated mice, except for carboplati-
num-treated mice (p = 0.021) (Fig 2B).
Fig 2. S. typhimuriumA1-R, trastuzumab and combination drug treatment of the patient cervical tumor grown in nudemice. (A) Growth curves of the
subcutaneous tumor treated with various drugs. The values are mean relative tumor volumes ± S.D. (bars) of five different tumors. * p < 0.05, ** p < 0.01. (B)
Body weight curves of the mice with the subcutaneous tumors treated with the indicated drugs. The values are mean relative body weights ± S.D. (bars) of
five different mice.
doi:10.1371/journal.pone.0120358.g002
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S. typhimurium A1-R + trastuzumab combination eradicates HER-
2-positive cervical cancer cells in mice as observed in histological
sections
Histopathological response to treatment was defined according to Evans’s grading scheme. In
tissue sections from untreated mice, numerous cancer cells were observed (Fig 3F). Approxi-
mately 30% of the cancer cells were destroyed and replaced by stromal cells in tissues sections
from mice treated with carboplatinum (Fig 3G). Seventy percent of the cancer cells were de-
stroyed in the tissue sections from mice treated with trastuzumab (Fig 3H). Sixty percent of the
cancer cells were destroyed in the tissue sections from mice treated with S. typhimurium A1-R
(Fig 3I). In the tissue sections from mice treated with S. typhimurium A1-R + trastuzumab, via-
ble cancer cells were not detected and were replaced by stromal cells (Fig 3J). The untreated
control was judged as grade I; carboplatinum treatment as IIa; trastuzumab treatment as IIb; S.
typhimurium A1-R treatment as IIb; and S. typhimurium A1-R + trastuzumab treatment as III
—IV. These results suggest the S. typhimurium A1-R + trastuzumab combination can eradicate
HER-2-positive cervical cancer in mice.
The mechanisms of the strong efficacy of the combination of S. typhimurium A1-R and tras-
tuzumab remains to be elucidated. One contributing factor could be the ability of S. typhimur-
ium A1-R to stimulate (decoy) the cell cycle of quiescent, resistant cells, which then begin to
Fig 3. Efficacy of S. typhimurium A1-R, trastuzumab and combination treatment on tumor size and
histology. (A) Untreated control. (B) Carboplatinum-treated mice. (C) Trastuzumab-treated mice. (D) S.
typhimurium A1-R-treated mice. (E) S. typhimurium A1-R + trastuzumab-treated mice. These images were
obtained at day-36. Scale bars: 10 mm. Histopathological response to treatment was defined according to
Evans’s grading scheme. Treatment effect of untreated control (F) was judged as grade I; carboplatinum (G)
as IIa; trastuzumab (H) as IIb; S. typhimurium A1-R (I) as IIb; and S. typhimurium A1-R + trastuzumab (J) as
III—IV. Scale bars: 200 μm.
doi:10.1371/journal.pone.0120358.g003
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cycle and become sensitive to trastuzumab [26]. Having found the strong efficacy of the combi-
nation of S. typhimurium A1-R and trastuzumab in subcutaneous models, future experiments
will utilize orthotopic models, using the surgical orthotopic implantation (SOI) method our
laboratory has developed for patient tumors [27–32]. Access of S. typhimurium A1-R to ortho-
topic tumors has been previously demonstrated by us [8–24]. Access to trastuzumab therapy in
orthotopic models has already been demonstrated by us as well [33]. The orthothopic models
of a series of HER-2 positive and mixed HER-2 expressing cervical cancer will allow efficacy
testing of the combination of S. typhimurium A1-R and trastuzumab against primary and met-
astatic disease and further characterization of stromal and cancer cells before and after treat-
ment, as well as the effects of leukocyte-depleting regimens following or before the treatment.
SOI requires surgery and since ketamine may affect the immune system, different anesthetics
will be compared for any effect on treatment response in future experiments.
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